Compare DexCom, Inc. (DXCM) vs McDonald's Corp (MCD) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

McDonald's (MCD) trades at $268.94, down 1.35% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, including a 31.62% net income margin and consistent revenue growth, reaching $26.89B in 2025. Recent news highlights the company's 'McDonald's NEXT' strategy focusing on automation and menu innovation to counter competition and inflation pressures.

The outlook remains positive with a consensus price target of $326.36, implying 21% upside, supported by 59.68% analyst buy ratings. Key risks include inflationary cost pressures on franchisee margins and high long-term debt of $38.42B. Earnings momentum is mixed, with a Q2 2026 estimate of $3.33 EPS to watch.